Background: Prone position (PP) is a recommended intervention in severe classical acute respiratory distress syndrome (ARDS). Changes in lung resting volume, respiratory mechanics and gas exchange during a 16-h cycle of PP in COVID-19 ARDS has not been yet elucidated.
Methods: Patients with severe COVID-19 ARDS were enrolled between May and September 2021 in a prospective cohort study in a University Teaching Hospital. Lung resting volume was quantitatively assessed by multiple breath nitrogen wash-in/wash-out technique to measure the end-expiratory lung volume (EELV). Timepoints included the following: Baseline, Supine Position (S1); start of PP (P0), and every 4-h (P4; P8; P12) until the end of PP (P16); and Supine Position (S2). Respiratory mechanics and gas exchange were assessed at each timepoint.
Measurements And Main Results: 40 mechanically ventilated patients were included. EELV/predicted body weight (PBW) increased significantly over time. The highest increase was observed at P4. The highest absolute EELV/PBW values were observed at the end of the PP (P16 vs S1; median 33.5 ml/kg [InterQuartileRange, 28.2-38.7] vs 23.4 ml/kg [18.5-26.4], < 0.001). Strain decreased immediately after PP and remained stable between P4 and P16. PaO/FiO increased during PP reaching the highest level at P12 (P12 vs S1; 163 [138-217] vs 81 [65-97], < 0.001). EELV/PBW, strain and PaO/FiO decreased at S2 although EELV/PBW and PaO/FiO were still significantly higher as compared to S1. Both absolute values over time and changes of strain and PaO/FiO at P16 and S2 versus S1 were strongly associated with EELV/PBW levels.
Conclusion: In severe COVID-19 ARDS, EELV steadily increased over a 16-h cycle of PP peaking at P16. Strain gradually decreased, and oxygenation improved over time. Changes in strain and oxygenation at the end of PP and back to SP were strongly associated with changes in EELV/PBW. Whether the change in EELV and oxygenation during PP may play a role on outcomes in COVID-ARDS deserves further investigation.
Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT04818164].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755177 | PMC |
| http://dx.doi.org/10.3389/fmed.2022.1056766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-based forecast of Helmet-CPAP therapy failure in Acute Respiratory Distress Syndrome patients.
Comput Methods Programs Biomed
December 2024
Politecnico di Milano, Dipartimento di Elettronica, Informazione e Bioingegneria, Piazza Leonardo Da Vinci 32, Milano, MI, 20133, Italy. Electronic address:
Background And Objective: Helmet-Continuous Positive Airway Pressure (H-CPAP) is a non-invasive respiratory support that is used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a severe medical condition diagnosed when symptoms like profound hypoxemia, pulmonary opacities on radiography, or unexplained respiratory failure are present. It can be classified as mild, moderate or severe. H-CPAP therapy is recommended as the initial treatment approach for mild ARDS.
View Article and Find Full Text PDFThe prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome.
Ann Intensive Care
January 2025
Department of Intensive Care, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Background: Extubation failure is associated with an increased morbidity, emphasizing the need to identify factors to further optimize extubation practices. The role of biomarkers in the prediction of extubation failure is currently limited. The aim of this study was to investigate the prognostic value of cardiac (N-terminal pro-B-type natriuretic peptide (NT-proBNP), High-sensitivity Troponin T (Hs-TnT)) and inflammatory biomarkers (Interleukin-6 (IL-6) and Procalcitonin (PCT)) for extubation failure in patients with COVID-19 Acute Respiratory Distress Syndrome (C-ARDS).
View Article and Find Full Text PDFCFTR as a therapeutic target for severe lung infection.
Am J Physiol Lung Cell Mol Physiol
January 2025
Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lung infection is one of the leading causes of morbidity and mortality worldwide. Even with appropriate antibiotic and antiviral treatment, mortality in hospitalized patients often exceeds 10%, highlighting the need for the development of new therapeutic strategies. Of late, cystic fibrosis transmembrane conductance regulator (CFTR) is - in addition to its well-established roles in the lung airway and extrapulmonary organs - increasingly recognized as a key regulator of alveolar homeostasis and defense.
View Article and Find Full Text PDFTocilizumab in COVID-19: A Double-Edged Sword?
Biomedicines
December 2024
Department of Anesthesia, Critical Care and Rescue Medicine, Collegium Medicum, University in Zielona Góra, 65-046 Zielona Góra, Poland.
SARS-CoV-2 was responsible for the global pandemic. Approximately 10-15% of patients with COVID-19 developed respiratory failure with adult acute respiratory distress syndrome (ARDS), which required treatment in the Intensive Care Unit (ICU). The cytokine storm observed in severe COVID-19 was frequently handled with steroids.
View Article and Find Full Text PDFDynamics of Biomarkers in COVID-19 Patients Treated with Anakinra.
Biomedicines
November 2024
Department of Infectious Diseases, Parasitology and Tropical Medicine, Medical University Sofia, 1431 Sofia, Bulgaria.
SARS-CoV-2 can trigger hyperinflammation, leading to severe COVID-19, presenting with pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ failure. Specific biomarkers like leukocytes, CRP, NLR, AST, LDH, D-dimer, ferritin, and IL-6 are associated with disease severity. Anakinra, an IL-1 receptor antagonist, has been proposed to mitigate hyperinflammation, but its clinical efficacy remains uncertain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!